UNSPSC 85812036: Introduction of monoclonal antibody into nose, external approach

This classification denotes the group of activities that yields a administrative intervention or procedure to introduction of monoclonal antibody into nose, external approach. This administrative intervention or procedure is listed in the World Health Organization's International Statistical Classification of Diseases and Related Health Problems or ICD-10 as code 3E09X0M

UNSPSC 85812036, Introduction of monoclonal antibody into nose, external approach, is a Commodity code that does not appear in recent state and local procurement activity. The code nominally describes a clinical procedure — intranasal monoclonal antibody administration — but the recent opportunities posted under it reflect a broad mix of health services unrelated to that specific intervention: virtual urgent care, general medical services, nursing home operations, cancer registry work, cancer screening, employee health clinics, occupational health services, EMS billing, medical directorships, psychological evaluation, histology services, travel nursing, telehealth platforms, recovery audit services, wellness programming, opioid treatment and recovery initiatives, behavioral health services, staffing for detention facilities, and radiology interpretation.

This mismatch between the code's nominal scope and actual procurement activity suggests either systematic miscoding in source systems or that the code has become a catch-all tag for state and local health services broadly. The issuing bodies include state departments (Colorado Department of Human Services, Texas HHSC, Nevada Health Authority, Illinois Secretary of State), county governments (DeKalb County Georgia, Santa Clara County, Ventura County, Sedgwick County Kansas, Jackson County Missouri), cities (Phoenix, Ocala, Atlanta, Boulder), school districts (Parkway School District), and health authorities (Inland Empire Health Plan). Recent activity spans California, Colorado, Georgia, Kansas, Nevada, Texas, Florida, Illinois, Virginia, New York, Oregon, Washington D.C., and multiple other jurisdictions. Without recent solicitations specifically calling for monoclonal antibody services or related biopharmaceutical administration, the code shows little relevant procurement signal for firms focused on that therapeutic category. Vendors should verify coding accuracy before pursuing opportunities posted under this code.